Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity

Brief Bioinform. 2021 Sep 13:bbab375. doi: 10.1093/bib/bbab375. Online ahead of print.ABSTRACTSince the outbreak of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, the viral genome has acquired numerous mutations with the potential to alter the viral infectivity and antigenicity. Part of mutations in SARS-CoV-2 spike protein has conferred virus the ability to spread more quickly and escape from the immune response caused by the monoclonal neutralizing antibody or vaccination. Herein, we summarize the spatiotemporal distribution of mutations in spike protein, and present recent efforts and progress in investigating the impacts of those mutations on viral infectivity and antigenicity. As mutations continue to emerge in SARS-CoV-2, we strive to provide systematic evaluation of mutations in spike protein, which is vitally important for the subsequent improvement of vaccine and therapeutic neutralizing antibody strategies.PMID:34518867 | DOI:10.1093/bib/bbab375
Source: Briefings in Bioinformatics - Category: Bioinformatics Authors: Source Type: research

Related Links:

New Brunswick, N.J. (October 19, 2021) – Johnson &Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson &Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5947-5964. doi: 10.26355/eurrev_202110_26872.ABSTRACTThe recent Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) outbreak has resulted in coronavirus disease 2019 (COVID-19) pandemic worldwide, affecting millions of lives. Although vaccines are presently made available, and vaccination drive is in progress to immunize a larger population; still the risk of SARS-CoV-2 infection and related mortality is persistent amid threats of the third wave of the ongoing pandemic. In the scenario of unavailability of robust and efficient treatment modalities, it becomes essential to...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSION: Outbreak response vaccination campaigns against cVDPV2 will be challenging throughout the COVID-19 pandemic but must be implemented urgently when feasible to stop transmission of cVDPV2.PMID:34629206 | DOI:10.1016/j.vaccine.2021.09.037
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.PMID:34620531 | DOI:10.1016/j.vaccine.2021.09.052
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
AbstractOn 11 March 2020, the World Health Organization declared the coronavirus disease 19 (COVID-19) outbreak a pandemic. In this context, several studies and clinical trials have been conducted since then, and many are currently ongoing, leading to the development of several COVID-19 vaccines with different mechanisms of action. People affected by multiple sclerosis (MS) have been considered high-risk subjects in most countries and prioritized for COVID-19 vaccination. However, the management of MS during the COVID-19 pandemic has represented a new challenge for MS specialists, particularly because of the initial lack o...
Source: Neurology and Therapy - Category: Neurology Source Type: research
On Oct. 6, the World Health Organization recommended use of the first vaccine to fight malaria. The decision is momentous and highly anticipated for many reasons: among them is that this is the first vaccine to help reduce the risk of deadly severe malaria in young children in Sub-Saharan Africa, where the disease remains a leading killer. The vaccine offers hope that there can be a circle of learning from one pandemic to the next. Malaria, our oldest pandemic, may offer insights on how we can survive contemporary scourges like COVID-19. Malaria evolved at least 2.5 million years ago and first infected humans in rural part...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized health healthscienceclimate Source Type: news
This study assessed the number of COVID-19 cases and potential secondary spread among 7,173 staff members and campers from 50 states, 13 countries, and U.S. military overseas bases at nine independently operated U.S. summer youth camps affiliated with the same organization. The camps implemented multiple prevention strategies including vaccination, testing, podding (cohorting), masking, physical distancing, and hand hygiene during June-August 2021. Vaccination coverage was 93% among eligible persons aged ≥12 years.† All staff members (1,955) and campers (5,218) received site-specific, protocol-defined screening t...
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Source Type: research
Comp Med. 2021 Oct 5. doi: 10.30802/AALAS-CM-21-000062. Online ahead of print.ABSTRACTThe significant advances made by the global scientific community during the COVID-19 pandemic, exemplified by thedevelopment of multiple SARS-CoV-2 vaccines in less than 1 y, were made possible in part because of animal research.Historically, animals have been used to study the characterization, treatment, and prevention of most of the major infectious disease outbreaks that humans have faced. From the advent of modern 'germ theory' prior to the 1918 Spanish Flu pandemic through the more recent Ebola and Zika virus outbreaks, research tha...
Source: Comparative Medicine - Category: Zoology Authors: Source Type: research
More News: Bioinformatics | COVID-19 | Outbreaks | Pandemics | SARS | Vaccines